Schroder Investment Management Group
FATE icon

Schroder Investment Management Group’s Fate Therapeutics FATE Stock Holding History

Schroder Investment Management Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-137,341
Closed -$1.39M – 1275
2022
Q4 		$1.39M Buy
137,341
+4,789
+4% +$89.9K ﹤0.01% 1007
2022
Q3 		$2.97M Buy
132,552
+68,673
+108% +$1.98M ﹤0.01% 868
2022
Q2 		$1.58M Buy
63,879
+998
+2% +$27.5K ﹤0.01% 1007
2022
Q1 		$2.51M Buy
62,881
+15,493
+33% +$600K ﹤0.01% 970
2021
Q4 		$2.77M Buy
47,388
+14,948
+46% +$847K ﹤0.01% 868
2021
Q3 		$1.92M Sell
32,440
-26,794
-45% -$2.1M ﹤0.01% 991
2021
Q2 		$5.14M Buy
59,234
+14,226
+32% +$1.15M 0.01% 823
2021
Q1 		$3.71M Sell
45,008
-32,943
-42% -$3.16M ﹤0.01% 885
2020
Q4 		$7.09M Sell
77,951
-9,957
-11% -$618K 0.01% 723
2020
Q3 		$3.35M Buy
87,908
+7,519
+9% +$263K 0.01% 801
2020
Q2 		$2.76M Sell
80,389
-12,614
-14% -$376K 0.01% 769
2020
Q1 		$2.31M Buy
93,003
+500
+0.5% +$12.6K ﹤0.01% 777
2019
Q4 		$1.81M Buy
+92,503
New +$1.47M ﹤0.01% 890

Other funds holding FATE

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Schroder Investment Management Group's FATE Position: Q1 2023 in Review

Schroder Investment Management Group sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 137,341 shares — an estimated $1.39M sold.

Schroder Investment Management Group first reported a position in FATE in Q4 2019 and held it in 13 quarters. The position peaked at $7.09M in Q4 2020. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • Schroder Investment Management Group reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Schroder Investment Management Group sold 137,341 Fate Therapeutics shares in Q1 2023, an estimated $1.39M.
  • Schroder Investment Management Group first reported a position in Fate Therapeutics in Q4 2019 and held it in 13 quarters.
  • Schroder Investment Management Group's Fate Therapeutics position peaked at $7.09M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on Schroder Investment Management Group's 13F filing for Q1 2023, filed 11 May 2023.